Literature DB >> 27313326

CXCL10: most consistent cGVHD biomarker?

Sophie Paczesny1, Mohammad Abu Zaid1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27313326      PMCID: PMC4911861          DOI: 10.1182/blood-2016-04-709543

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Authors:  Joanne E Croudace; Charlotte F Inman; Ben E Abbotts; Sandeep Nagra; Jane Nunnick; Prem Mahendra; Charles Craddock; Ram Malladi; Paul A H Moss
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

3.  CXCR3 in T cell function.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

4.  Role of CXCR3-induced donor T-cell migration in acute GVHD.

Authors:  Ulrich Duffner; Bao Lu; Gerhard C Hildebrandt; Takanori Teshima; Debra L Williams; Pavan Reddy; Rainer Ordemann; Shawn G Clouthier; Kathy Lowler; Chen Liu; Craig Gerard; Kenneth R Cooke; James L M Ferrara
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

5.  Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Authors:  Carrie L Kitko; John E Levine; Barry E Storer; Xiaoyu Chai; David A Fox; Thomas M Braun; Daniel R Couriel; Paul J Martin; Mary E Flowers; John A Hansen; Lawrence Chang; Megan Conlon; Bryan J Fiema; Rachel Morgan; Prae Pongtornpipat; Kelly Lamiman; James L M Ferrara; Stephanie J Lee; Sophie Paczesny
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

6.  Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Leigh A Corrion; Krystyna M Olkiewicz; Bao Lu; Kathleen Lowler; Ulrich A Duffner; Bethany B Moore; William A Kuziel; Chen Liu; Kenneth R Cooke
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

7.  Identification and validation of biomarkers associated with acute and chronic graft versus host disease.

Authors:  S S Ahmed; X N Wang; J Norden; K Pearce; E El-Gezawy; S Atarod; I Hromadnikova; M Collin; E Holler; A M Dickinson
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

8.  High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Nazmim S Bhuiya; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

9.  Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Authors:  Amina Kariminia; Shernan G Holtan; Sabine Ivison; Jacob Rozmus; Marie-Josée Hebert; Paul J Martin; Stephanie J Lee; Daniel Wolff; Peter Subrt; Sayeh Abdossamadi; Susanna Sung; Jan Storek; Megan Levings; Mahmoud Aljurf; Mukta Arora; Corey Cutler; Geneviève Gallagher; John Kuruvilla; Jeff Lipton; Thomas J Nevill; Laura F Newell; Tony Panzarella; Joseph Pidala; Gizelle Popradi; David Szwajcer; Jason Tay; Cynthia L Toze; Irwin Walker; Stephen Couban; Barry E Storer; Kirk R Schultz
Journal:  Blood       Date:  2016-03-28       Impact factor: 22.113

  9 in total
  6 in total

Review 1.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

Review 2.  Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.

Authors:  Sophie Paczesny
Journal:  Br J Haematol       Date:  2020-02-10       Impact factor: 6.998

3.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

4.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Authors:  Mohammad Abu Zaid; Juan Wu; Cindy Wu; Brent R Logan; Jeffrey Yu; Corey Cutler; Joseph H Antin; Sophie Paczesny; Sung Won Choi
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

5.  Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.

Authors:  Sencer Goklemez; Annie P Im; Liang Cao; Filip Pirsl; Seth M Steinberg; Lauren M Curtis; Sandra A Mitchell; Edward W Cowen; Judy Baruffaldi; Jeremy Rose; Jacqueline Mays; Alen Ostojic; Noa G Holtzman; Frances T Hakim; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2020-01-25       Impact factor: 13.265

Review 6.  Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.

Authors:  Hadir Shakshouk; Eric R Tkaczyk; Edward W Cowen; Rokea A El-Azhary; Shahrukh K Hashmi; Saad J Kenderian; Julia S Lehman
Journal:  Transplant Cell Ther       Date:  2021-06-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.